• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@Artvin
  • Meslek Yüksekokulları
  • Sağlık Hizmetleri Meslek Yüksekokulu
  • Sağlık Hizmetleri Meslek Yüksekokulu Makale Koleksiyonu
  • View Item
  •   DSpace@Artvin
  • Meslek Yüksekokulları
  • Sağlık Hizmetleri Meslek Yüksekokulu
  • Sağlık Hizmetleri Meslek Yüksekokulu Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: anin silicostructure-based approach

Thumbnail

View/Open

mutlu_ozal.pdf (4.695Mb)

Access

info:eu-repo/semantics/openAccess

Date

2020

Author

Mutlu, Özal
Uğurel, Osman Mutluhan
Sarıyer, Emrah
Ata, Oğuz
İnci, Tuğba Gül
Uğurel, Erennur
Koçer, Sinem
Turgut Balık, Didem

Metadata

Show full item record

Citation

Mutlu, O., Uğurel, O. M., Sarıyer, E., Ata, O., İnci, T. G., Uğurel, E., ... & Turgut-Balık, D. (2020). Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach. Journal of Biomolecular Structure and Dynamics, 1-13.

Abstract

In this study, the Nsp12-Nsp8 complex of SARS-CoV-2 was targeted with structure-based and computer-aided drug design approach because of its vital role in viral replication. Sequence analysis of RNA-dependent RNA polymerase (Nsp12) sequences from 30,366 different isolates were analysed for possible mutations. FDA-approved and investigational drugs were screened for interaction with both mutant and wild-type Nsp12-Nsp8 interfaces. Sequence analysis revealed that 70.42% of Nsp12 sequences showed conserved P323L mutation, located in the Nsp8 binding cleft. Compounds were screened for interface interaction, any with XP GScores lower than -7.0 kcal/mol were considered as possible interface inhibitors. RX-3117 (fluorocyclopentenyl cytosine) and Nebivolol had the highest binding affinities in both mutant and wild-type enzymes, therefore they were selected and resultant protein-ligand complexes were simulated for analysis of stability over 100 ns. Although the selected ligands had partial mobility in the binding cavity, they were not removed from the binding pocket after 100 ns. The ligand RX-3117 remained in the same position in the binding pocket of the mutant and wild-type enzyme after 100 ns MD simulation. However, the ligand Nebivolol folded and embedded in the binding pocket of mutant Nsp12 protein. Overall, FDA-approved and investigational drugs are able to bind to the Nsp12-Nsp8 interaction interface and prevent the formation of the Nsp12-Nsp8 complex. Interruption of viral replication by drugs proposed in this study should be further tested to pave the way forin vivostudies towards the treatment of COVID-19.

Source

Journal of Biomolecular Structure and Dynamics

Volume

Article in Press

URI

https://hdl.handle.net/11494/2798

Collections

  • Sağlık Hizmetleri Meslek Yüksekokulu Makale Koleksiyonu [31]
  • Scopus İndeksli Yayınlar Koleksiyonu [525]
  • WoS İndeksli Yayınlar Koleksiyonu [685]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Policy | Guide | Contact |
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Policy || Guide || Library || Artvin Çoruh University || OAI-PMH ||

Artvin Çoruh University, Artvin, Turkey
If you find any errors in content, please contact:

Creative Commons License
Artvin Çoruh University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Artvin:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.